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ABSTRACT 
 
Background    
Indwelling pleural catheter (IPC) is an established management option for malignant pleural 
effusion (MPE) and has advantages over talc slurry pleurodesis. The optimal regimen of 
drainage after IPC insertion remains debated and ranges from aggressive (daily) drainage to 
drainage only when symptomatic.  
 
Methods    
AMPLE-2 was an open-labelled, randomized trial that involved 11 centers in Australia, New 
Zealand, Hong Kong and Malaysia between July 2015 and January 2017 
[ACTRN12615000963527]. Patients (n=87) with symptomatic MPEs were randomized (1:1) 
to the Aggressive (daily) or Symptom-guided drainage arms for 60 days and minimized by 
cancer type (mesothelioma vs others), performance status (ECOG 0-1 vs ≥2), presence of 
trapped lung and prior pleurodesis, and followed up for 6 months. The results were analyzed 
by an intention-to-treat approach. 
 
Findings    
The primary outcome compared the mean daily breathlessness scores of each patient, measured 
using a 100mm visual analogue scale (VAS), over the first 60 days and found no significant 
difference between the Aggressive and Symptom-guided drainage arms (geometric 
means=13·1 vs 17·3 mm respectively, p=0·1766, ratio of geometric means 1·32, 95% CI 0·88-
1·97). More patients in the Aggressive arm developed spontaneous pleurodesis than in the 
Symptom-guided arm in the first 60 days (37·2% [16/43] vs 11·4% [5/44] respectively, 
p=0·0049) and at 6 months (44·2% [19/43] vs 15·9% [7/44] respectively, p=0·0065; HR=3·287 
[95% CI 1·396-7·740]). Patient-reported quality-of-life measures, using EQ-5D-5L, were 
better in the Aggressive arm than in the Symptom-guided arm: estimated means 0·713 (95% CI 
0·647-0·779) vs 0·601 (95% CI 0·536-0·667) respectively. The estimated difference in means 
was 0·112 (95% CI 0·0198-0·204), p=0·0174. There were no significant between-group 
differences in pain scores, total days spent in hospital or mortality. Serious adverse events 
occurred in 25.6% (11/43) and 27.3% (12/44) patients in the Aggressive and Symptom-guided 
drainage arms respectively, including 11 episodes of pleural infection in 9 patients (5 in the 
Aggressive arm and 6 in the Symptom-guided drainage arm). 
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Interpretation    
No differences were found between the aggressive (daily) and the symptom-guided drainage 
regimens for IPC in providing breathlessness control. Patients managed with the two schedules 
did not differ on their pain scores, days spent in hospital or mortality. Daily IPC drainage is 
more effective in promoting spontaneous pleurodesis and may improve quality-of-life.   
 
Funding        
This trial has received funding support from Cancer Council of Western Australia and the Sir 
Charles Gairdner Research Advisory Group. The investigators have received research 
fellowship support from the National Health and Medical Research Council, NHMRC, (SM, 
RT, YCGL), the Cancer Council WA (RT), and the WA Cancer and Palliative Care Network 
(SM, MA, RT). YCGL is a NHMRC/Medical Research Future Fund Next Generation 
Practitioner Fellow of Australia and has received project grant funding from the NHMRC, New 
South Wales Dust Diseases Authority, Sir Charles Gairdner Research Advisory Committee, 
Institute for Respiratory Health, Cancer Australia and Cancer Council of Western Australia. 
LG received funding support from Wesley Medical Research Funding. 
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INTRODUCTION 
 
Malignant pleural effusion (MPE) can complicate most cancers.1 The associated breathlessness 
is often distressing, debilitating, and significantly impairs quality-of-life (QoL).2 MPE 
accounts for over 125,000 hospital admissions per year in the USA alone.3 
 
Indwelling pleural catheter (IPC) is a new therapeutic approach for MPE and its advantages 
have been confirmed in recent randomized trials.4,5 Treatment with IPC significantly reduces 
days spent in hospital and the need for further invasive pleural procedures in patients’ 
remaining life,4 compared with conventional talc slurry pleurodesis, while offering the same 
level of symptom and QoL improvement.4,5 IPC is increasingly adopted worldwide as the first 
line management for MPE. 
 
The logical next goal is to optimize the use of IPC and hence its benefits. Few data exist to 
guide drainage approaches for IPC patients. Practices vary worldwide, ranging from aggressive 
(daily or alternate day) drainage, often used in North American centers,6 to drainage only when 
symptoms develop which is common in the rest of the world.  These differences in practice 
may potentially influence outcome and complication rates.   
 
Aggressive daily drainage arguably keeps the pleural space dry and provides best symptom 
control everyday whereas those who advocate symptom-guided drainage contend that the goal 
of MPE care is palliation and drainage of IPC is only indicated when symptoms arise.  The 
symptom-guided approach may reduce a significant amount of burden and consumable costs 
compared with daily drainages, and may reduce the risk of iatrogenic introduction of pleural 
infection.  
 
On the other hand, it is believed that frequent IPC drainage may facilitate approximation of the 
visceral and parietal pleura and facilitate their symphysis (‘spontaneous’ pleurodesis), and 
allow removal of the catheter. Daily drainage has been shown to promote pleurodesis more 
effectively than alternative day drainage.6 Whether a symptom-guided approach affects the rate 
of pleurodesis is unknown. 
 
The Australasian Malignant PLeural Effusion (AMPLE) Trial-2 was a multi-centered, open-
labelled, randomized clinical trial (RCT) designed to address the equipoise between Aggressive 
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(daily) versus Symptom-guided approaches to IPC drainage in patients with a MPE, specifically 
their efficacy in breathlessness control, induction of pleurodesis, improvement of QoL and the 
associated hospitalization and complication rates.7    
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METHODS 
 
The study was a randomized, multicenter, open-label trial. Study participants were enrolled 
(see published study protocol7) from 11 centers: Sir Charles Gairdner, Fiona Stanley, Royal 
Perth, Saint John of God Bunbury, Sunshine Coast University, Royal Adelaide, Wesley, and 
St George & The Sutherland Hospitals in Australia; Middlemore Hospital in New Zealand; 
Queen Elizabeth Hospital, Kota Kinabalu, in Malaysia; and Queen Mary Hospital Hong Kong. 
Ethics and governance approvals were obtained from the human research ethics committee at 
all sites, the primary committee being the Sir Charles Gairdner and Osborne Park Health Care 
Group Human Research and Ethics Committee (2014-079). Written, informed consent was 
obtained from all participants.  
 
Eligibility: All participants enrolled were adults who required IPC placement for management 
of a MPE. All participants had malignant cells identified in the pleural fluid or pleural biopsy 
tissue; or a large exudative pleural effusion without other causes in a patient with known 
disseminated extra-pleural malignancy. Exclusion criteria included age <18 years, expected 
survival <3 months, pleural infection, chylothorax, pregnancy, lactation, un-correctable 
bleeding diathesis, previous ipsilateral lobectomy/pneumonectomy, significant loculations 
likely to preclude effective fluid drainage, significant visual impairment and inability to 
consent or comply with the study protocol.  
 
Randomisation and Masking: The randomization was performed independently by the 
National Health & Medical Research Council (NHMRC) Clinical Trials Centre, University of 
Sydney, Australia.  Participants were randomized 1:1 to aggressive (daily) or symptom-guided 
drainage via their IPC, using an automated telephone-based voice-response randomization 
service. Randomization code generation was assigned sequentially as participants underwent 
the randomization process. Randomization was minimized for i) cancer type (mesothelioma vs 
non-mesothelioma), ii) performance status (Eastern Cooperative Oncology Group [ECOG] 0-
1 vs ≥2), iii) presence of trapped lung (vs not) and iv) prior pleurodesis (vs not). Trapped lung 
was defined as air or fluid in the pleural space occupying ≥25% of the lateral chest wall after 
initial drainage. Minimization is a dynamic method; as such there was no ‘sequence’. 
Allocation concealment was additionally maintained by incorporating an ‘imbalance window’ 
(set at 3) within which treatments were completely random (the order of the random allocations 
was maintained within the NHMRC Clinical Trials Centre secure database). Participants who 
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withdrew from the trial were not replaced. It was not practical or possible to mask the 
participants or those giving the interventions. 
 
Trial Intervention: IPC (Rocket Medical plc, UK) was inserted as per standard clinical 
practice. Participants were randomized within 72 hours of IPC insertion after maximum pleural 
fluid evacuation to ensure the same baseline for all participants. In the Aggressive drainage 
arm, participants (and/or their carers/community nurses) were asked to drain their MPE via the 
IPC every day for the first 60 days unless clinically contraindicated or spontaneous pleurodesis 
had occurred. For the Symptom-guided arm, participants performed drainage when they had 
effusion-related symptoms (usually breathlessness, cough and/or chest tightness). IPC was 
accessed at least fortnightly to ensure the catheter remained patent and to assess if fluid was 
still being produced.   
 
Participants were supplied with standard IPC vacuum-suction bottles (600mL) for fluid 
drainage following instructions of the manufacturer (Rocket Medical plc, UK). Pleurodesis was 
defined as <50mL of fluid removed at three consecutive drainages6 (in the Aggressive drainage 
arm) or at two attempts two weeks apart (in the Symptom-guided arm), and in the absence of 
significant residual pleural fluid collections on imaging.  
 
All participants and carers were given standard IPC education on the drainage method, 
aftercare and potential complications, and had ready access to support services (eg via direct 
phone line) for any concerns. They were free to receive other treatments including chemo-
irradiation and palliative care as recommended by treating clinicians. Participants were 
followed up for a minimum of 6 months after randomization or until death, whichever occurred 
sooner. The drainage regimen after 60 days was left to the discretion of the attending clinicians. 
 
Participants kept a logbook of their breathlessness score recorded every day for 60 days then 
weekly until the end of the study. The breathlessness score was measured using a validated 
100mm visual analog scale (VAS), a 100mm line anchored with ‘best breathing’ at 0mm and 
‘worst breathing imaginable’ at 100mm. The pain level was also measured on a 100mm VAS 
scale which was anchored with ‘no pain’ at 0mm and ‘worst imaginable pain’ at 100mm.8 The 
volume of pleural fluid removed at each drainage was also recorded.  
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Baseline clinical data, VAS scores for breathlessness4,5,9 and pain, and QoL (VAS and 
EuroQoL-5 Dimensions-5 Levels [EQ-5D-5L]10) measures were collected prior to IPC 
insertion and post-randomization (72 hours after IPC insertion). Participants were reviewed at 
2 and 4 weeks, and thereafter monthly for 6 months. Details of any hospital admissions were 
recorded, including duration, adverse events and clinical management. 
 
Outcomes: The primary outcome was the mean daily breathlessness score in the first 60 days 
post randomization. The VAS scores were measured by two independent assessors and the 
average of their readings recorded. Both assessors repeated their measurements separately if 
initial readings differed by >3mm. If discrepancies persisted, the assessors would re-score and 
discuss to reach a consensus.  
 
Secondary outcomes included  
(a) rates of spontaneous pleurodesis; 
(b) self-reported global QoL measurements using two instruments, namely the EQ-5D-5L11,12 
and a 100mm VAS at randomization (after maximal fluid drainage), at pre-determined clinic 
follow-up visits 2 and 4 weeks post-randomization, and thereafter monthly up to 6 months. 
The EQ-5D-5L score consisted of 5 domains – mobility, self-care, usual activities, 
discomfort/pain and anxiety/depression. Each domain was graded by the patient from 1 (‘no 
problems’) to 5 (‘worst’). QoL score was also measured with a 100mm line anchored with ‘best 
QoL’ at 0mm and ‘worst QoL’ at 100mm;  
(c) total number of episodes and duration of hospitalization for any cause (excluding elective 
admissions for chemotherapy). The latter was subdivided into pleural-related (or not) hospital 
days, as defined previously,4 from randomization to death or end of 6-month follow-up;  
(d) frequency of adverse (AE) and serious adverse events (SAEs).  These events were then 
assessed by an independent reviewer for relatedness to trial intervention; 
(e) survival. 
 
Statistical Analyses: Data were analyzed on an intention-to-treat basis and supporting analyses 
were carried out adjusting for minimization variables measured at randomization of 
mesothelioma, ECOG score, the presence of a trapped lung and prior pleurodesis, in addition 
to the random effect of study center, where appropriate. All data were analyzed using the R 
environment for statistical computing13 and SAS/STAT software v9.4 (Raleigh, NC, USA).   
 
 10 
 
The study was planned to enroll at least 86 patients to detect a mean difference of VAS score 
of 14mm between the treatment arms (5% significance, 90% power) assuming a common 
between-group standard deviation (S.D.) of 18.9mm (based on a previous RCT of IPC5) and a 
10% lost-to-follow up rate. The minimal clinical important difference (MCID) for the VAS 
score in this setting is 19mm (95% CI 14-24mm) as per Mishra et al.9 The lower end of the CI 
of 14mm was used for this power calculation.   
 
The difference in breathlessness scores and pain scores between the two treatment arms was 
analyzed using a two sample t test on the log transformed average scores over the first 60 days 
of the trial. Results are back transformed and presented as geometric means and 95% 
confidence intervals (CIs) and compared through a ratio of the geometric means.  A two sample 
t test was used to compare the difference in rates of logbook completion between the two 
groups.  
 
Time to spontaneous pleurodesis was analyzed using the Fine and Gray competing risks 
survival model, with competing risk being death and described with the cumulative incidence 
curve. Time to death was analyzed using Kaplan-Meier survival curves and Cox proportional 
hazards models.  For all time to event analyses, hazard ratios (HR) (95% CIs) comparing the 
two treatment arms are provided.  Differences in proportions of survival and spontaneous 
pleurodesis between the treatment arms were compared using chi-squared tests for 
independence or Fisher’s exact tests. All patient hospitalization data were analyzed using 
Mann-Whitney tests to compare the two treatment arms with supporting analyses using 
negative binomial regression models.  The EQ-5D-5L11,12 scores were converted into a single 
index value that generates a measure of utility ranging from -0.111 to 1.000 (1.000 indicates 
full health) using an online tool.14 A crosswalk value set15 was used to obtain the index value, 
as no EQ-5D-5L value set was available specifically for the countries included in this study.  
Linear mixed models were used to compare EQ-5D-5L index values and log-transformed VAS 
(QoL) between the two treatment arms. Fixed effects of treatment, time and the treatment by 
time interaction and random patient and center effects were included in the model along with 
effects of minimization variables and, in supporting analyses, the effect of baseline index 
values.  Differences in least squared means (95% CI) or ratios of geometric means (95% CI) 
are provided. When the logbook entries were incomplete, supporting sensitivity analyses were 
carried out using multiple imputation with chain equations of 40 imputed datasets.   
 
 11 
 
This trial is registered with the Australian New Zealand Clinical Trial Registry (ANZCTR) - 
ACTRN12615000963527. 
 
Role of the funding source: The funders had no role in the design and conduct of the study; 
collection, management, analysis and interpretation of the data; preparation, review or approval 
of the manuscript; and decision to submit the manuscript for publication. SM and YCGL have 
full access to all of the data in the study and take responsibility for the integrity of the data and 
the accuracy of the data analyses. 
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RESULTS   
 
Participants (n=87; 41 males; median age 66·8 [59·1–74·3] years) were recruited between 20th 
July 2015 and 26th January 2017 and randomized to the Aggressive (n=43) or Symptom-guided 
(n=44) drainage arms. The groups were well matched in their age, gender, proportions of 
primary malignancies and trapped lung, effusion size, comorbidities, baseline symptom scores 
and ECOG status (Table 1). The most common underlying malignancies were lung cancer 
(n=34), mesothelioma (n=29) and ovarian carcinoma (n=10).  
 
Those randomized to the Aggressive arm performed in total 1420 drainages (median 39 [IQR 
13-57] drainages per subject) up to 60 days (the intervention period), time of pleurodesis or 
death (whichever earliest), out of a possible 1518 drainages, confirming good compliance.  
Participants of the Symptom-guided cohort performed 535 drainages (median 11 [IQR 7-18] 
per subject) in the same period. At the end of the six month follow-up period, the total number 
of drainages performed in the subjects in the Aggressive and the Symptom-guided drainage 
arms were 1999 and 1035 respectively.   
                          
Primary End-Point  Data were analyzed on an intention-to-treat basis (Figure 1). Five 
patients did not return their logbook and therefore had no breathlessness score data; they were 
excluded from the primary end point analysis. There was no significant difference in the 
compliance rates of reporting the daily breathlessness scores between the two groups 
(Aggressive arm=81·8% vs Symptom-guided arm=79·7%, p=0·74).  
 
The primary endpoint compared the average VAS breathlessness scores of each participant 
over the first 60 days of study and found no significant difference between the two treatment 
groups (Aggressive drainage arm geometric mean=13·1 (95% CI 9·8-17·4) vs Symptom-
guided drainage arm geometric mean=17·3 (95% CI 13·0-22·0), p=0·18; ratio of geometric 
means 1·32, 95% CI 0·88-1·97), Figure 2. This was further supported in analyses adjusting for 
minimization variables and including random center effects (Aggressive drainage arm 
geometric mean=16·3 (95% CI 11.3-23.7) vs Symptom-guided drainage arm geometric 
mean=21.0 (95% CI 14·8-29·7), p=0·21; ratio of geometric means 1·28, 95% CI 0·86-1·91)  
and was consistent when multiple imputation was carried out to account for missing logbook 
entries.    
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Secondary End-points  
  
Spontaneous pleurodesis   Significantly more patients in the Aggressive arm 
developed spontaneous pleurodesis (n=16, 37·2%) than in the Symptom-guided arm (n=5, 
11·4%) in the first 60 days, p=0·0049, and by 6 months [n=19 (44·2%) vs n=7 (15·9%) 
respectively, p=0·004]. From the competing risk survival model the HR comparing Aggressive 
to Symptom-guided groups for achieving spontaneous pleurodesis was 3·287 (95% CI 1·396-
7·740, p=0·0065), Figure 3. These results were consistent after adjusting for minimization 
variables (HR=3.429, 95% CI 1·413-8·320, p=0·0064).  
 
We compared patients with non-trapped (n=59) and trapped lungs (n=28) in a post-hoc 
analysis. Spontaneous pleurodesis was more common in those with non-trapped lungs than in 
those with trapped lungs (n=17 vs 4, 28·8% vs 14·3% respectively) at 60 days but not by 6 
months (n=18 vs 8; 30·5% vs 28·6% respectively). In the Aggressive drainage arm, 
spontaneous pleurodesis developed in 41·4% of those with non-trapped lungs (vs 28·6% in the 
trapped lung group) at 60 days and 41·4% (vs 50·0%) at 6 months. In the Symptom-guided arm, 
spontaneous pleurodesis developed in 16·7% of those with non-trapped lungs (vs 0·0% in those 
with trapped lungs) at 60 days and 20·0% (vs 7·1%) at 6 months. The Kaplan-Meier estimated 
median time to pleurodesis was 121 days in the Aggressive arm, including those with trapped 
and non-trapped lungs. The success rate was too low in the Symptom-guided arm to provide a 
reliable Kaplan-Meier estimate of the median time to pleurodesis. 
 
Pain scores   The mean (SD) of the VAS pain scores over the first 60 days of 
the trial was 10·74 (12·80) in the Aggressive arm and 16·31 (16·58) in the Symptom-guided 
arm (Figure 4), and there was no significant difference between the treatment (ratio of 
geometric means=1·28, 95% CI 0·76-2·18, p=0·35).  
 
QoL Scores    In a linear mixed model on response to EQ-5D-5L, no interaction 
between time and treatment was detected and the significant main effect of treatment arm 
indicated that the averaged EQ-5D-5L index values over the study period/visits were higher 
(i.e. better QoL) in the Aggressive arm than in the Symptom-guided arm: estimated means 0·713 
(95% CI 0·647-0·779) vs 0·601 (95% CI 0·536-0·667) respectively. The estimated difference 
in means was 0·112 (95% CI 0·0198-0·204), p=0·0174. This was consistent after adjusting for 
minimization variables and baseline EQ-5D-5L index values (estimated difference in 
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means=0·097, 95% CI 0.004-0.191, p=0.0408).  No between-group differences were found in 
the VAS (QoL) scores during the study visits (ratio of geometric means=1·220, 95% CI 0·871-
1·709, p=0·25). For all visit times for both treatments there was concordance in the measures of 
EQ-5D-5L and the VAS QoL with statistically significant correlations at most of the visit times 
and moderate to high correlations throughout (see Online Supplementary). 
 
Hospital admissions and total number of days in hospital  The median number of 
hospital admissions was 1 [IQR 0-2] for the first 60 days and 2 [1-3] at 6 months for the entire 
cohort.  Overall, the trial patients spent 1 [IQR 0-8] day in total in hospital by 60 days and 5 
[0-15] days by 6 months. There were no differences between the Aggressive drainage and the 
Symptom-guided drainage arms in the number of hospital admissions or duration spent in 
hospital either in total number of days or when only the effusion-related admissions were 
included (as defined in our previous trial4), Table 2. These results were consistent after 
adjusting for days in trial and other minimization variables. 
 
Patients with better (ECOG 0-1) performance status spent fewer effusion-related days in 
hospital at 60 days (1 [IQR 0-2] vs 2 [0-6] days, p=0.0392) and by 6 months (1 [IQR 0-4] vs 2 
[0-6] days, p=0·0339) than those of ECOG ≥2.  Trapped lung at baseline was associated with 
fewer episodes of hospital admissions (1 [IQR 0-2] vs 2 [1-3] without trapped lung, p=0·0406), 
total (2·5 [IQR 0-6] vs 6 [1-19] days, p=0·0013) and effusion-related days in hospital (1 [IQR 
0-3] vs 1 [0-6] day, p=0·0158) at 6 months. 
 
Mortality    No significant differences were observed between the treatments 
for time to death at 6 months (Aggressive vs Symptom-guided drainage arms HR 0·951; 95% 
CI 0·499-1·812, p=0·88), see Kaplan-Meier analyses (Figure 5).  In the first 60 days, 10 
(23·3%) individuals in the Aggressive drainage arm and 9 (20·5%) in the Symptom-guided 
drainage arm died (estimiated difference in proportions=0·028, 95% CI -0·146-0·202, 
p=0·75). By 6 months, 18 (41·9%) patients in the Aggressive drainage arm and 19 (43·2%) in 
the Symptom-guided drainage arm had died (estimiated difference in proportions=-0·013, 95% 
CI -0·221-0·195, p=0·90).  
 
Patients with better performance status by ECOG score also had longer survival (HR for death 
for better to poorer ECOG status=0·399, 95% CI 0·203-0·785, p=0·0078) at 6 months.  
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Adverse events  The total number and proportion of patients experiencing ≥1 AE 
or SAE are presented (Table 3). Of the 32 SAEs and 46 AEs recorded, 11 (four SAEs, and 
seven AEs) were deemed definitely not related to trial intervention by an independent assessor. 
Eleven patients in the Aggressive drainage arm and 12 in the Symptom-guided drainage arm 
had experienced SAEs. AEs (n=46) occurred in 13 and 22 patients in the Aggressive drainage 
and Symptom-guided drainage arms respectively. In the Symptom-guided arm, the most 
common adverse event was pain at IPC site pain requiring narcotics (n=12). Worsening 
dyspnea due to ipsilateral pleural effusion despite drainage occurred in six patients which 
usually responded well to increasing drainage frequency.  
 
Eleven episodes of pleural infection developed (n=5 vs 6 in the Aggressive drainage and 
Symptom-guided drainage arms respectively) in 9 patients over 6 months. Four patients had 
their IPC removed at the time of infection and three others developed pleurodesis post-
infection. There were no deaths related to IPC infection. 
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DISCUSSION   
 
This multicenter RCT found no differences between the aggressive (daily) and the symptom-
guided drainage approaches in providing breathlessness control over the first 60 days post-IPC 
insertion. There were no significant between-group differences in pain, days spent in hospital 
or survival. Aggressive drainage was associated with a higher rate of pleurodesis and better 
EQ-5D-5L index values. Serious adverse events were uncommon in either group.   
 
MPEs are common and affect about one-third of those with lung and breast cancers and the 
majority of mesothelioma patients. MPE often heralds incurable cancers and limited 
prognosis.16 Control of the associated breathlessness frequently requires invasive pleural 
procedures. IPC presents an alternative to conventional talc pleurodesis, and has been shown 
to reduce hospitalization4,5,17 and need for repeat pleural interventions in the patients’ 
remaining lifespan.4,5 The use of IPC is growing rapidly, especially in developed countries, and 
is often advocated as the first-line definitive therapy for MPE.18 Ambulatory IPC drainages do 
require resources (time of carers/community nurses and consumables) and theoretically can 
introduce infections.19 Two schools of IPC management, aggressive and symptom-guided 
drainage approaches, have evolved and are at equipoise.  
 
Our study found no significant differences in breathlessness control, the principal goal of MPE 
palliation, whether the patients perform drainages daily or as guided by symptoms. The data 
are reassuring and imply that if assigned to do so, patients were able to recognize early, or 
anticipate, their symptoms and perform drainages before any discomfort reached a level of 
impact.  
 
However, aggressive daily fluid removal did promote more effective pleurodesis. Keeping the 
pleural cavity fluid-free theoretically allows better approximation of the visceral and parietal 
pleura and thus adhesion formation and pleural fibrosis/symphysis. Conversely, permitting 
‘asymptomatic’ accumulation of the pleural fluid in between symptom-guided drainages may 
have physically impaired pleural symphysis. A prior RCT also found that spontaneous 
pleurodesis occurred more commonly with daily than alternate day drainages.6    
 
Most spontaneous pleurodesis in the Aggressive drainage arm developed within the first 60 
days, consistent with timeframe from published data.6,20 In our protocol, the drainage schedules 
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after 60 days were left to the choice of the attending clinicians and patients. It is possible that 
without the suggestion of slowing down of drainage, many patients would have adopted a less 
aggressive approach. Whether prolonging daily drainage beyond 60 days will facilitate late 
pleurodesis requires further research.  
 
Our study is one of the very few RCTs that included patients with trapped lung, which 
accounted for a third of the cohort, consistent with commonly quoted data. Those with trapped 
lung had (expectedly) a lower rate of pleurodesis than those with expandable lung, though 
aggressive drainage was still associated with a higher pleurodesis rate even in the trapped lung 
group. The exact mechanism will need exploration although it is possible that in some cases 
the trapped lung can slowly expand with time (and/or concurrent therapy) and allow pleural 
symphysis. Alternatively, the trapped space may be small and when sufficient 
adhesions/loculations develop over time, no further fluid drainage is necessary. Nonetheless, 
future studies should incorporate trapped lung patients to guide best care.  
 
Reassuringly, aggressive drainage was not associated with more pain or infection. IPC-related 
pleural infection affected about 5% of patients in our previous international study.21 Daily 
access of the catheter may increase risks of introducing microbes; however, pleural drainage is 
the key to empyema management and aggressive drainage may ensure prompt removal of any 
microbes that have entered the pleural cavity.  There were also no major differences in other 
serious adverse events or survival between the two arms. More AEs were observed in the 
Symptom-guided drainage arm especially dyspnea attributed to pleural effusion, most of which 
responded to increased frequency of drainage.  
 
Patients in the Aggressive drainage arm reported better EQ-5D-5L index values, despite no 
clear benefits in their reported breathlessness or pain scores. There is no MCID specifically 
assigned for patients with MPE for EQ-5D-5L or VAS-QoL. In our study, the between-group 
difference of the EQ-5D-5L index value was 0.112 which is above the MCID defined by 
Pickard et al22 (=0.09) in advanced cancer patients. It is possible that daily removal of the fluid 
provided benefits in symptoms not captured with our breathlessness and pain measurements. 
The higher pleurodesis rate, with resultant freedom from fluid (and symptom) recurrence and 
of the catheter, may have contributed to the better reported QoL. Additionally, it has been 
suggested that IPC drainage gives patients an important sense of control when they are feeling 
helpless with their advancing cancer. Whether this can explain the scores remains to be tested. 
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The two QoL instruments both showed improvements and there exists good correlations of the 
values between the EQ-5D-5L and VAS-QoL at each time point.  The between-group 
differences were significant with EQ-5D-5L but not with VAS-QoL.  This may be related to 
the sensitivity of the instruments in detecting changes in this patient population, but this is a 
topic for future studies.  
 
Developing the full potential of IPC in MPE care is a topic of active research. Combining IPC 
with pleurodesis, either by instillation20 via the catheter or coating23 of the catheter with a 
pleurodesing agent, appears promising. Defining the best drainage regimen will hold an even 
more important role if instillation of pleurodesing agents becomes routine practice. A newly 
published randomized trial20 showed that instillation of talc slurry (followed by IPC drainage 
2-3 times a week) induced a higher rate of pleurodesis than saline control. However, the success 
rate in the talc arm was low (~43%), similar to what was achieved with our Aggressive drainage 
arm (without talc). Our trial, and the ASAP study,6 both confirmed that daily IPC fluid removal 
enhances spontaneous pleurodesis, which is adopted now into protocols of ongoing studies (eg 
EPIToME and OPTIMUM24) evaluating talc instillation via IPC.  
 
Our study has limitations. First, the primary endpoint was set at 60 days as it reflects the short 
median survival of MPE from lung cancers (the most common type of MPE globally). We have 
however also included many MPEs from mesothelioma (the subtype with longest median 
survival among common causes of MPEs). Our results did not differ between the non-
mesothelioma and mesothelioma patients. Second, the definition of ‘spontaneous pleurodesis’ 
used in existing literature describes cessation of fluid formation, which may relate to treatment 
or natural disease course, but not necessarily symphysis of the visceral and parietal pleura (the 
true meaning of ‘pleurodesis’). Ultrasound assessment was available in a subset of 18 patients 
who had ‘spontaneous pleurodesis’ in the lead center; all but one achieved sonographic 
appearances of pleural symphysis. Third, the consumable/carer costs of daily drainage varied 
substantially among centers around the world. However, this study has provided an idea of the 
amount of drainage consumables needed for aggressive and symptom-guided drainage and 
would allow clinicians to estimate their local costs of each regimen. Fourth, as our study is an 
open label study, there can be potential of introducing bias with the use of patient reported 
measures. 
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Recently published and ongoing RCTs in MPE management have provided data supporting the 
use of IPC as first choice definitive management in MPE,4,5,25,26 but realizing its full potential 
depends on employing the optimal drainage schedule. This present trial showed that either 
aggressive or symptom-guided drainage regimens are adequate in breathlessness control. 
However, daily fluid removal enhances spontaneous pleurodesis and may improve QoL 
without any drawbacks in relation to pain, infection rates or survival. In patients where 
pleurodesis is an important goal, e.g. those undertaking strategies of IPC plus pleurodesing 
agents, aggressive drainage should be employed for at least 60 days. Future studies will need 
to establish if more aggressive, e.g. twice daily, regimens for the initial phase may further 
enhance success rates.27 On the other hand, for patients whose primary care aim is palliation, 
e.g. those with very limited life expectancy or significant trapped lung where pleurodesis is 
unlikely, our data showed that symptom-guided drainage offers an effective means of 
breathlessness control without the incovenience and costs of daily drainages. The ability to 
predict likelihood of pleurodesis will help guide choice of regimen and should be a topic of 
future studies.        
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LEGENDS 
 
 
 
Figure 1: Trial profile 
 
Figure 2. The average VAS breathlessness scores of each individual patient over the first 60 
days by treatment group are presented. The minimal clinically important difference of this 
instrument is 19mm for malignant pleural effusion patients.  The horizontal lines indicate the 
median values.  
 
 
Figure 3.   Cumulative incidence curve of pleurodesis success rate based on 6 months data 
estimated from Fine and Gray competing risks model. Note: Three individuals withdrew from 
the study during the 6 month follow-up: one from the Aggressive arm at 173 days and two from 
the Symptom-guided arm at 52 and 97 days.  
 
 
Figure 4. The average VAS pain scores of each individual patient over the first 60 days of the 
trial are presented.  The horizontal lines indicate the median values.  
 
Figure 5.   Kaplan-Meier curve of survival at 6 months  
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Figure 1: Trial profile 
 
 
# 74 patients were screened but found ineligible for the following reasons:  
Expected survival < 3 months (n=27); unable to comply with protocol (n=12); 
effusion did not have histo-cytological confirmation as malignant (n=7); effusion not causing 
symptoms (n=4); critical illness (n=3); significant loculations (n=3); chylothorax (n=2); un-
correctable bleeding diathesis (n=2); inability to consent (n=2); previous ipsilateral IPC 
(n=2); visual impairment (n=1); concurrent pleural infection (n=1); previous ipsilateral 
lobectomy (n=1); not specified (n=7). 
 
 5 patients (2 in Aggressive and 3 in Symptom-guided arm) did not return any logbook data 
for primary endpoint analysis.  
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Figure 2. The average VAS breathlessness scores of each individual patient over the first 60 
days by treatment group are presented. The minimal clinically important difference of this 
instrument is 19mm for malignant pleural effusion patients.  The horizontal lines indicate the 
median values.  
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Figure 3.   Cumulative incidence curve of pleurodesis success rate based on 6 months data 
estimated from Fine and Gray competing risks model. Note: Three individuals withdrew from 
the study during the 6 month follow-up: one from the Aggressive arm at 173 days and two from 
the Symptom-guided arm at 52 and 97 days.  
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Figure 4. The average VAS pain scores of each individual patient over the first 60 days of the 
trial are presented.  The horizontal lines indicate the median values.  
 
 
 
 
 
 28 
 
Figure 5.   Kaplan-Meier curve of survival at 6 months  
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Table 1.  Summary statistics of baseline measures are provided by treatment arm including 
counts and percentages for categorical variables.    
  
Aggressive  Symptom-guided  
drainage drainage 
(n=43) (n=44) 
Age (median [IQR] years) 65·1 [57·8-72·5] 68·0 [60·8-75·0] 
Male gender   n= (%) 21 (49%) 20 (45%) 
Side of intervention: right     n= (%) 27 (63%) 31 (71%) 
Type of primary malignancy    n= (%) 
  Mesothelioma 15 (35%) 14 (32%) 
  Non-mesothelioma 28 (65%) 30 (68%) 
  Lung 17 (40%) 17 (39%) 
  Breast 0 (0%) 4 (9%) 
  Ovarian 6 (14%) 4 (9%) 
  Other 5 (12%) 5 (11%) 
Trapped lung    n= (%) 14 (33%) 14 (32%) 
Previous Talc Pleurodesis    n= (%) 4 (9%) 7 (16%) 
ECOG Performance Status 
  0 – 1 30 (70%) 30 (68%) 
  ≥2 13 (30%) 14 (32%) 
Comorbidities    n= (%) 
  Respiratory 8 (19%) 13 (30%) 
  Cardiac 9 (21%) 8 (18%) 
  Depression/Anxiety 9 (21%) 6 (14%) 
  Diabetes 6 (14%) 6 (14%) 
Effusion size grade #      n= (%) 
  Small (0 – 1) 1 (2%) 1 (2%) 
  Moderate (2 – 3) 13 (30%) 14 (32%) 
  Large (4 – 5) 29 (67%) 29 (66%) 
Baseline self-reported symptom scores mean (SD) 
  VAS breathlessness score (mm)  28·1 (20·3) 28·3 (20·7) 
  VAS QoL score (mm) 36·4 (22·4) 29·8 (19·9) 
  EQ-5D-5L index score 0·681 (0·177) 0·611 (0·231) 
  EQ-5D-5L Score by modality median [IQR] 
  Mobility 1 [1-2] 2 [1-3] 
  Self-care 1 [1-2] 1 [1-2] 
  Usual activities  2 [2-3] 2 [1-3] 
  Pain/Discomfort 2 [2-3] 2 [2-3] 
 30 
 
  Depression/Anxiety 1 [1-2] 2 [1-2] 
Chemotherapy in preceding 30 days n= (%) 9 (21%) 11 (25%) 
 
 
ECOG=Eastern Cooperative Oncology Group. VAS=Visual Analog Scale. QoL= quality-of-
life. IQR=interquartile range.  EQ-5D-5L = EuroQoL-5 Dimensions-5 levels. 
 
# Baseline effusion size was graded on chest radiograph using a validated grading system 
whereby grade 0 referred to no radiographic evidence of pleural fluid; grade 1 = blunting of 
the costophrenic angle; grade 2 to 5 referred to fluid occupying <25%, 25 to 50%, 51 to 75% 
and >75% of the hemithorax respectively.20 This scale has previously been used to predict 
pleurodesis and indwelling pleural catheter use in patients with a malignant pleural 
effusion.21 
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Table 2. Data of hospital admissions in episodes and duration by treatment groups. All values 
presented as median [IQR]. 
 
 
 
 Aggressive   
Drainage 
(n=43) 
Symptom-
guided 
Drainage 
(n=44) 
 
p = 
Episodes of hospital admission 
First 60 days 
At 6 months 
 
1 [0-2] 
2 [1-4] 
 
1 [0-2]  
2 [1-3] 
 
0·74 
0·80 
Total days spent in hospital 
First 60 days 
At 6 months 
 
1 [0-7] 
5 [0-15] 
1.5 [0-8] 
4 [1-15.5] 
0·84 
0·52 
Effusion-related hospitalization days 
First 60 days 
At 6 months 
 
1 [0-4] 
1 [0-5] 
1 [0-3] 
1 [0-5] 
0·74 
0·70 
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Table 3.  Adverse and Serious Adverse Events by treatment groups.   
 
Type of Events 
Aggressive  
Drainage 
(n=43) 
Symptom-
guided 
Drainage 
(n=44) 
Total Serious Adverse Events (SAE)   n= 16 16 
Total Adverse Events (AE)   n= 14 32 
TOTAL AEs and SAEs 30 48 
   
Number of patients affected by a SAE   n=  11 12 
Number of patients affected by an AE   n=  13 22 
 
Events assessed to be ‘Definitely’, ‘Probably’, ‘Possibly’, or ‘Unlikely’ related to trial 
intervention by an independent assessor 
Serious Adverse Events   n= 
Pleural Infection 5 6 
Symptomatic loculation 3 5 
Air leak/Pneumothorax 2 1 
Recurrence needing re-intervention post IPC removal 1 1 
IPC site cellulitis requiring hospital admission 2 0 
IPC blockage requiring hospital admission 0 1 
Worsening dyspnea (effusion related) requiring hospital 
admission 
0 1 
Adverse Events   n= 
IPC blockage 1 3 
IPC site cellulitis 1 2 
Pain requiring narcotics 
     IPC site 
     Related to suction bottle 
 
7 
1 
 
12 
1 
IPC leakage 0 1 
IPC valve dislodged 0 1 
Worsening dyspnea 
     Effusion related 
     Recurrence needing re-intervention 
     Not effusion related 
 
1 
0 
0 
 
6 
1 
1 
   
Events assessed to be ‘definitely not related’ to trial intervention   
 6  5 
 
